+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The tag Optic Neuromyelitis Drug returned 0 results.

No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.

Optic Neuromyelitis (ON) is a rare neurological disorder that affects the optic nerve and spinal cord. It is characterized by inflammation of the optic nerve and spinal cord, resulting in vision loss and neurological deficits. Treatment of ON is typically focused on reducing inflammation and preventing further damage. Clinical trials are an important part of the development of new treatments for ON. These trials are designed to evaluate the safety and efficacy of potential treatments, as well as to identify any potential side effects. The Optic Neuromyelitis Drug market is a rapidly growing field, with a number of companies developing new treatments for ON. These companies are focused on developing treatments that are safe and effective, while also minimizing side effects. Companies in this market include Biogen, Novartis, and Merck, among others. Show Less Read more